|
CA2726861C
(en)
|
2008-02-13 |
2014-05-27 |
Intarcia Therapeutics, Inc. |
Devices, formulations, and methods for delivery of multiple beneficial agents
|
|
AU2010272944B2
(en)
|
2009-07-13 |
2015-11-19 |
Zealand Pharma A/S |
Acylated glucagon analogues
|
|
RU2547990C2
(ru)
|
2009-09-28 |
2015-04-10 |
Интарсия Терапьютикс, Инк. |
Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства
|
|
JP6006118B2
(ja)
|
2009-12-16 |
2016-10-12 |
ノヴォ ノルディスク アー／エス |
Ｇｌｐ−１アナログ及び誘導体
|
|
JP6039569B2
(ja)
*
|
2010-11-09 |
2016-12-07 |
ノヴォ ノルディスク アー／エス |
二重アシル化されたｇｌｐ−１誘導体
|
|
SI2651398T1
(en)
|
2010-12-16 |
2018-04-30 |
Novo Nordisk A/S |
SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND SOL N- (8- (2-HYDROXYBENZOIL) AMINO) CAPRICULATE ACIDS
|
|
US20120208755A1
(en)
*
|
2011-02-16 |
2012-08-16 |
Intarcia Therapeutics, Inc. |
Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
|
|
PL2696687T3
(pl)
|
2011-04-12 |
2017-06-30 |
Novo Nordisk A/S |
Pochodne podwójnie acylowanej GLP-1
|
|
BR112014001274A2
(pt)
|
2011-07-18 |
2017-04-18 |
Arts Biologics As |
composto de hormônio luteinizante, e, composição farmacêutica
|
|
JP6126097B2
(ja)
*
|
2011-09-06 |
2017-05-10 |
ノヴォ ノルディスク アー／エス |
Ｇｌｐ−１誘導体
|
|
CN110041399B
(zh)
|
2011-12-29 |
2023-12-12 |
诺沃—诺迪斯克有限公司 |
包含非成蛋白质性的氨基酸的二肽
|
|
US9452225B2
(en)
|
2012-03-01 |
2016-09-27 |
Novo Nordisk A/S |
GLP-1 prodrugs
|
|
PT2827845T
(pt)
|
2012-03-22 |
2019-03-29 |
Novo Nordisk As |
Composições compreendendo um agente de entrega e sua preparação
|
|
HRP20181447T1
(hr)
|
2012-03-22 |
2018-11-02 |
Novo Nordisk A/S |
Pripravci glp-1 peptida i njihova priprava
|
|
IN2014MN02304A
(https=)
|
2012-05-03 |
2015-08-07 |
Zealand Pharma As |
|
|
CN104411322B
(zh)
*
|
2012-05-08 |
2017-05-24 |
诺和诺德股份有限公司 |
双酰化glp‑1衍生物
|
|
EP2846823B1
(en)
|
2012-05-08 |
2019-12-04 |
Novo Nordisk A/S |
Double-acylated glp-1 derivatives
|
|
EP2851429B1
(en)
|
2012-05-18 |
2019-07-24 |
Adda Biotech Inc. |
Protein and protein conjugate for diabetes treatment, and applications thereof
|
|
JP6517690B2
(ja)
|
2012-06-20 |
2019-05-22 |
ノヴォ ノルディスク アー／エス |
ペプチド及び送達剤を含む錠剤製剤
|
|
EP2866825B1
(en)
|
2012-07-01 |
2020-04-08 |
Novo Nordisk A/S |
Use of long-acting glp-1 peptides
|
|
IN2015DN00544A
(https=)
|
2012-07-23 |
2015-06-26 |
Zealand Pharma As |
|
|
FR2994848B1
(fr)
|
2012-08-30 |
2014-08-22 |
Univ Paris Curie |
Traitement de l'arthrose par les hormones incretines ou leurs analogues
|
|
TWI608013B
(zh)
|
2012-09-17 |
2017-12-11 |
西蘭製藥公司 |
升糖素類似物
|
|
UA116217C2
(uk)
|
2012-10-09 |
2018-02-26 |
Санофі |
Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
|
|
EP2915817B1
(en)
*
|
2012-10-31 |
2018-06-20 |
Hybio Pharmaceutical Co., Ltd. |
Method for preparing exenatide
|
|
AU2013366692B2
(en)
|
2012-12-21 |
2017-11-23 |
Sanofi |
Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists
|
|
KR102272671B1
(ko)
*
|
2013-05-02 |
2021-07-06 |
노보 노르디스크 에이/에스 |
Glp-1 화합물의 경구 투여
|
|
JP6475233B2
(ja)
*
|
2013-06-20 |
2019-02-27 |
ノヴォ ノルディスク アー／エス |
Ｇｌｐ−１誘導体及びその使用
|
|
EP3016975B1
(en)
|
2013-07-04 |
2019-01-16 |
Novo Nordisk A/S |
Derivatives of glp-1 like peptides, and uses thereof
|
|
EP3033112B1
(en)
|
2013-08-15 |
2020-10-07 |
Novo Nordisk A/S |
Glp-1 derivatives, and uses thereof
|
|
JP6822839B2
(ja)
|
2013-09-13 |
2021-01-27 |
ザ・スクリップス・リサーチ・インスティテュート |
修飾された治療剤、及びその組成物
|
|
US9988429B2
(en)
|
2013-10-17 |
2018-06-05 |
Zealand Pharma A/S |
Glucagon analogues
|
|
PL3057984T3
(pl)
|
2013-10-17 |
2018-12-31 |
Zealand Pharma A/S |
Acylowane analogi glukagonu
|
|
WO2015067715A2
(en)
|
2013-11-06 |
2015-05-14 |
Zealand Pharma A/S |
Gip-glp-1 dual agonist compounds and methods
|
|
CN105829339B
(zh)
|
2013-11-06 |
2021-03-12 |
西兰制药公司 |
胰高血糖素-glp-1-gip三重激动剂化合物
|
|
US10626156B2
(en)
|
2013-12-06 |
2020-04-21 |
Jie Han |
Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
|
|
EP3080154B1
(en)
|
2013-12-13 |
2018-02-07 |
Sanofi |
Dual glp-1/gip receptor agonists
|
|
EP3080152A1
(en)
|
2013-12-13 |
2016-10-19 |
Sanofi |
Non-acylated exendin-4 peptide analogues
|
|
WO2015086728A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
|
|
WO2015086733A1
(en)
|
2013-12-13 |
2015-06-18 |
Sanofi |
Dual glp-1/glucagon receptor agonists
|
|
KR102455171B1
(ko)
|
2013-12-18 |
2022-10-14 |
더 스크립스 리서치 인스티튜트 |
변형된 치료제, 스테이플드 펩티드 지질 접합체, 및 이의 조성물
|
|
TW201625669A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
|
|
TW201625668A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
|
|
TW201625670A
(zh)
|
2014-04-07 |
2016-07-16 |
賽諾菲公司 |
衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
|
|
ES2741507T3
(es)
*
|
2014-04-07 |
2020-02-11 |
Novo Nordisk As |
Compuestos de glp-1 acilados doblemente
|
|
EP3973994A1
(en)
|
2014-06-12 |
2022-03-30 |
RA Pharmaceuticals, Inc. |
Modulation of complement activity
|
|
US9932381B2
(en)
|
2014-06-18 |
2018-04-03 |
Sanofi |
Exendin-4 derivatives as selective glucagon receptor agonists
|
|
US9889085B1
(en)
|
2014-09-30 |
2018-02-13 |
Intarcia Therapeutics, Inc. |
Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
|
|
KR102620911B1
(ko)
|
2014-10-29 |
2024-01-05 |
질랜드 파마 에이/에스 |
Gip 효능제 화합물 및 방법
|
|
JP6730278B2
(ja)
*
|
2014-11-27 |
2020-07-29 |
ノヴォ ノルディスク アー／エス |
Ｇｌｐ−１誘導体及びその使用
|
|
WO2016097108A1
(en)
|
2014-12-17 |
2016-06-23 |
Novo Nordisk A/S |
Glp-1 derivatives and uses thereof
|
|
US9937222B2
(en)
|
2015-01-28 |
2018-04-10 |
Ra Pharmaceuticals, Inc. |
Modulators of complement activity
|
|
JP7211704B2
(ja)
*
|
2015-01-29 |
2023-01-24 |
ノヴォ ノルディスク アー／エス |
Ｇｌｐ－１アゴニスト及び腸溶コーティングを含む錠剤
|
|
US20180263915A1
(en)
*
|
2015-01-29 |
2018-09-20 |
Novo Nordisk A/S |
Pharmaceutical Composition for Oral GLP-1 Administration Comprising a Tablet Core and Immediate Release Coating
|
|
DK3283507T3
(da)
|
2015-04-16 |
2020-01-02 |
Zealand Pharma As |
Acyleret glucagonanalog
|
|
RU2730996C2
(ru)
|
2015-06-03 |
2020-08-26 |
Интарсия Терапьютикс, Инк. |
Системы установки и извлечения имплантата
|
|
AU2016270373A1
(en)
|
2015-06-05 |
2018-01-04 |
Vertex Pharmaceuticals Incorporated |
Triazoles for the treatment of demyelinating diseases
|
|
AR105319A1
(es)
|
2015-06-05 |
2017-09-27 |
Sanofi Sa |
Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
|
|
EP3319968A1
(en)
|
2015-07-06 |
2018-05-16 |
Rodin Therapeutics, Inc. |
Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
|
|
WO2017007756A1
(en)
|
2015-07-06 |
2017-01-12 |
Rodin Therapeutics, Inc |
Hetero-halo inhibitors of histone deacetylase
|
|
TW201706291A
(zh)
|
2015-07-10 |
2017-02-16 |
賽諾菲公司 |
作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
|
|
CN106496322A
(zh)
*
|
2015-09-07 |
2017-03-15 |
江苏恒瑞医药股份有限公司 |
人胰岛素或其类似物的酰化衍生物的制备方法
|
|
EP3368556B1
(en)
*
|
2015-10-28 |
2024-04-10 |
Tufts University |
Novel polypeptides with improved proteolytic stability, and methods of preparing and using same
|
|
RU2733720C2
(ru)
|
2015-12-16 |
2020-10-06 |
Ра Фармасьютикалз, Инк. |
Модуляторы активности комплемента
|
|
GB2551945B
(en)
*
|
2015-12-18 |
2021-09-08 |
Heptares Therapeutics Ltd |
Novel GLP-1 receptor agonist peptides
|
|
US10946074B2
(en)
|
2016-03-03 |
2021-03-16 |
Novo Nordisk A/S |
GLP-1 derivatives and uses thereof
|
|
KR102574993B1
(ko)
|
2016-05-16 |
2023-09-06 |
인타르시아 세라퓨틱스 인코포레이티드 |
글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
|
|
USD860451S1
(en)
|
2016-06-02 |
2019-09-17 |
Intarcia Therapeutics, Inc. |
Implant removal tool
|
|
USD840030S1
(en)
|
2016-06-02 |
2019-02-05 |
Intarcia Therapeutics, Inc. |
Implant placement guide
|
|
CN107561168A
(zh)
*
|
2016-06-30 |
2018-01-09 |
山东新时代药业有限公司 |
一种聚乙二醇化促胰岛素分泌肽类似物的分析检测方法
|
|
ES2828526T3
(es)
|
2016-11-07 |
2021-05-26 |
Novo Nordisk As |
Esteres activos DCHBS de compuestos PEG y sus usos
|
|
WO2018106646A1
(en)
|
2016-12-06 |
2018-06-14 |
Vertex Pharmaceuticals Incorporated |
Aminotriazoles for the treatment of demyelinating diseases
|
|
WO2018106641A1
(en)
|
2016-12-06 |
2018-06-14 |
Vertex Pharmaceuticals Incorporated |
Pyrazoles for the treatment of demyelinating diseases
|
|
WO2018106643A1
(en)
|
2016-12-06 |
2018-06-14 |
Vertex Pharmaceuticals Incorporated |
Heterocyclic azoles for the treatment of demyelinating diseases
|
|
KR20190093196A
(ko)
|
2016-12-07 |
2019-08-08 |
라 파마슈티컬스 인코포레이티드 |
보체 활성의 조절인자
|
|
JP7286542B2
(ja)
|
2017-01-03 |
2023-06-05 |
インターシア セラピューティクス，インコーポレイティド |
Ｇｌｐ－１受容体アゴニストの持続的投与及び薬物の同時投与を含む方法
|
|
HUE057849T2
(hu)
|
2017-01-11 |
2022-06-28 |
Alkermes Inc |
Hiszton deacetiláz biciklusos gátlói
|
|
FR3061715B1
(fr)
|
2017-01-12 |
2021-07-30 |
Institut National Univ Jean Francois Champollion |
Peptide immunomodulateur
|
|
MX2019010651A
(es)
*
|
2017-03-08 |
2020-01-13 |
Intarcia Therapeutics Inc |
Aparato y métodos para administración de un compuesto nauseogénico desde un dispositivo de administración de fármacos.
|
|
TWI797133B
(zh)
|
2017-06-09 |
2023-04-01 |
丹麥商諾佛 儂迪克股份有限公司 |
用於經口投予的固體組成物
|
|
LT3664802T
(lt)
|
2017-08-07 |
2022-06-27 |
Alkermes, Inc. |
Bicikliniai histonų deacetilazės inhibitoriai
|
|
KR102665710B1
(ko)
|
2017-08-24 |
2024-05-14 |
노보 노르디스크 에이/에스 |
Glp-1 조성물 및 그 용도
|
|
KR102396217B1
(ko)
*
|
2017-09-19 |
2022-05-09 |
임문워크 아이엔씨 |
알부민과의 결합 친화성이 증대된 약학 구조물
|
|
CA3078652A1
(en)
|
2017-10-12 |
2019-04-18 |
Novo Nordisk A/S |
Semaglutide in medical therapy
|
|
JP6898518B2
(ja)
|
2018-02-02 |
2021-07-07 |
ノヴォ ノルディスク アー／エス |
Ｇｌｐ−１アゴニスト、ｎ−（８−（２−ヒドロキシベンゾイル）アミノ）カプリル酸の塩及び滑沢剤を含む固形組成物
|
|
MX2020010505A
(es)
|
2018-04-05 |
2021-01-15 |
Sun Pharmaceutical Ind Ltd |
Analogos novedosos de glp-1.
|
|
US11633459B2
(en)
|
2018-05-04 |
2023-04-25 |
Novo Nordisk A/S |
GIP derivatives and uses thereof
|
|
TWI829687B
(zh)
|
2018-05-07 |
2024-01-21 |
丹麥商諾佛 儂迪克股份有限公司 |
包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
|
|
CN109134257A
(zh)
*
|
2018-10-08 |
2019-01-04 |
扬州工业职业技术学院 |
一种两步法制备高纯度十二烷基二酸单叔丁酯的方法
|
|
CN109111361A
(zh)
*
|
2018-10-08 |
2019-01-01 |
扬州工业职业技术学院 |
一种一步法高效制备十二烷基二酸单叔丁酯的方法
|
|
WO2020118843A1
(zh)
*
|
2018-12-12 |
2020-06-18 |
四川利通科创生物医药科技有限公司 |
一种glp-1突变体及其制备方法和用途
|
|
MA54807A
(fr)
|
2019-01-24 |
2022-04-27 |
Novo Nordisk As |
Compacteur à rouleaux et procédé de granulation à sec utilisant un compacteur à rouleaux
|
|
WO2020180534A1
(en)
|
2019-03-01 |
2020-09-10 |
President And Fellows Of Harvard College |
Methods and compositions for protein delivery
|
|
KR20220004066A
(ko)
|
2019-04-03 |
2022-01-11 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
약물 전달용 이온성 액체
|
|
JP2022535411A
(ja)
|
2019-06-04 |
2022-08-08 |
ラ ファーマシューティカルズ インコーポレイテッド |
補体阻害剤による炎症性疾患治療
|
|
WO2021070202A1
(en)
*
|
2019-10-09 |
2021-04-15 |
Prasad Alaparthi Lakshmi |
A method for preparing glp-1 analogue by solid-phase peptide synthesis
|
|
IL291876A
(en)
|
2019-11-06 |
2022-06-01 |
Novo Nordisk As |
Receptor agonists in glp-1 type dementia
|
|
WO2021089752A1
(en)
|
2019-11-07 |
2021-05-14 |
Novo Nordisk A/S |
Solid compositions comprising a glp-1 agonist, an sglt2 inhibitor and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
|
|
CA3158963A1
(en)
|
2019-11-22 |
2021-05-27 |
Samir Mitragotri |
Ionic liquids for drug delivery
|
|
MX2022006861A
(es)
|
2019-12-04 |
2022-07-11 |
Scripps Research Inst |
Agonistas del receptor glp2 y metodos de uso.
|
|
EP4085077A4
(en)
|
2019-12-31 |
2024-01-17 |
Beijing QL Biopharmaceutical Co., Ltd. |
Fusion proteins of glp-1 and gdf15 and conjugates thereof
|
|
JP7761567B2
(ja)
|
2020-02-18 |
2025-10-28 |
ノヴォ ノルディスク アー／エス |
医薬製剤
|
|
GB202003762D0
(en)
*
|
2020-03-16 |
2020-04-29 |
Heptares Therapeutics Ltd |
GLP receptor agonists
|
|
CN115461044B
(zh)
|
2020-04-29 |
2025-06-10 |
诺和诺德股份有限公司 |
包含glp-1激动剂和组氨酸的固体组合物
|
|
CN114222755B
(zh)
*
|
2020-05-29 |
2024-06-11 |
北京拓界生物医药科技有限公司 |
Glp-1和gip受体双重激动剂化合物及其应用
|
|
EP4181946A1
(en)
*
|
2020-07-18 |
2023-05-24 |
Dr. Reddy's Laboratories Ltd. |
Improved purification process of semaglutide
|
|
EP4185607A1
(en)
|
2020-07-22 |
2023-05-31 |
Novo Nordisk A/S |
Co-agonists at glp-1 and gip receptors suitable for oral delivery
|
|
CN114729060B
(zh)
*
|
2020-09-30 |
2022-11-25 |
北京质肽生物医药科技有限公司 |
多肽缀合物和使用方法
|
|
WO2022096636A1
(en)
|
2020-11-06 |
2022-05-12 |
Novo Nordisk A/S |
Glp-1 prodrugs and uses hereof
|
|
TWI850611B
(zh)
*
|
2020-12-18 |
2024-08-01 |
丹麥商諾佛 儂迪克股份有限公司 |
Glp-1及澱粉素受體之共促效劑
|
|
CN114685644A
(zh)
*
|
2020-12-29 |
2022-07-01 |
苏州康宁杰瑞生物科技有限公司 |
一种人glp-1多肽变体及其应用
|
|
WO2022175384A1
(en)
*
|
2021-02-17 |
2022-08-25 |
Fundación Universidad Católica De Valencia San Vicente Mártir |
Small-molecule agents with antiviral activity against rna viruses
|
|
KR20240032010A
(ko)
|
2021-06-09 |
2024-03-08 |
더 스크립스 리서치 인스티튜트 |
장기 지속형 이중 gip/glp-1 펩타이드 접합체 및 사용 방법
|
|
WO2023012263A1
(en)
|
2021-08-04 |
2023-02-09 |
Novo Nordisk A/S |
Solid oral peptide formulations
|
|
EP4412587A1
(en)
|
2021-10-08 |
2024-08-14 |
President And Fellows Of Harvard College |
Ionic liquids for drug delivery
|
|
AU2022386166A1
(en)
|
2021-11-10 |
2024-06-20 |
I2O Therapeutics, Inc. |
Ionic liquid compositions
|
|
CN116650424A
(zh)
*
|
2022-01-06 |
2023-08-29 |
鸿绪生物医药科技（北京）有限公司 |
新型多肽制剂及其治疗用途
|
|
TW202330584A
(zh)
|
2022-01-20 |
2023-08-01 |
丹麥商諾佛 儂迪克股份有限公司 |
前藥及其用途
|
|
EP4323413A4
(en)
|
2022-03-30 |
2025-10-15 |
Beijing Ql Biopharmaceutical Co Ltd |
LIQUID PHARMACEUTICAL COMPOSITIONS OF POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF
|
|
AR129270A1
(es)
|
2022-05-10 |
2024-08-07 |
Novo Nordisk As |
Profármacos y usos de los mismos
|
|
CA3260606A1
(en)
|
2022-06-30 |
2024-01-04 |
Sanofi |
NEW PEPTIDES FOR USE AS SELECTIVE IL-23 RECEPTOR ANTAGONISTS
|
|
CN116514952B
(zh)
*
|
2022-10-13 |
2024-02-02 |
江苏师范大学 |
一类glp-1类似物及其应用
|
|
TW202421645A
(zh)
|
2022-11-25 |
2024-06-01 |
丹麥商諾佛 儂迪克股份有限公司 |
如ｇｌｐ—１之肽治療劑的口服投與
|
|
JP2026502943A
(ja)
|
2022-12-30 |
2026-01-27 |
アルギファルマ エーエス |
経口投与されるポリペプチド治療剤の全身バイオアベイラビリティを高める組成物および方法
|
|
WO2024245946A1
(en)
*
|
2023-05-26 |
2024-12-05 |
Gubra A/S |
Secretin-derived glp1r selective agonists
|
|
CN120676965A
(zh)
*
|
2023-11-07 |
2025-09-19 |
深圳信立泰药业股份有限公司 |
多重受体共激动剂化合物及其制备方法与应用
|
|
WO2026072611A1
(en)
*
|
2024-09-24 |
2026-04-02 |
Eli Lilly And Company |
Tirzepatide binding molecules, and uses thereof
|